Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretroviral treatment-experienced adults, in combination with a boosted protease inhibitor and other antiretrovirals.

Etravirine is the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be launched in 10 years and it is the first NNRTI to show antiviral activity in treatment experienced adult patients resistant to NNRTIs.

Intelence has been authorised under a ‘conditional approval' scheme which means new information on etravirine will be reviewed yearly and the SPC updated as necessary.

View Intelence drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Medicines shortages increase as prescribing costs rise £158 million

Medicines shortages increase as prescribing costs rise £158 million

Increasing medicines shortages have added more than...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MHRA urges GPs to ensure continued INR monitoring during pandemic

MHRA urges GPs to ensure continued INR monitoring during pandemic

The MHRA advice was issued following reports of an...